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a b s t r a c t
Introduction: Target delineation variability is a significant technical impediment in multi-institutional
trials which employ intensity modulated radiotherapy (IMRT), as there is a real potential for clinically
meaningful variances that can impact the outcomes in clinical trials. The goal of this study is to determine
the variability of target delineation among participants from different institutions as part of Southwest
Oncology Group (SWOG) Radiotherapy Committee’s multi-institutional in-silico quality assurance study
in patients with Pancoast tumors as a ‘‘dry run” for trial implementation.
Methods: CT simulation scans were acquired from four patients with Pancoast tumor. Two patients had
simulation 4D-CT and FDG-FDG PET-CT while two patients had 3D-CT and FDG-FDG PET-CT. Seventeen
SWOG-affiliated physicians independently delineated target volumes defined as gross primary and nodal
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tumor volumes (GTV_P & GTV_N), clinical target volume (CTV), and planning target volume (PTV).
Six board-certified thoracic radiation oncologists were designated as the ‘Experts’ for this study. Their
delineations were used to create a simultaneous truth and performance level estimation (STAPLE) con-
tours using ADMIRE software (Elekta AB, Sweden 2017). Individual participants’ contours were then com-
pared with Experts’ STAPLE contours.
Results: When compared to the Experts’ STAPLE, GTV_P had the best agreement among all participants,
while GTV_N showed the lowest agreement among all participants. There were no statistically significant
differences in all studied parameters for all TVs for cases with 4D-CT versus cases with 3D-CT simulation
scans.
Conclusions: High degree of inter-observer variation was noted for all target volume except for GTV_P,
unveiling potentials for protocol modification for subsequent clinically meaningful improvement in tar-
get definition. Various similarity indices exist that can be used to guide multi-institutional radiotherapy
delineation QA credentialing.
 2019 The Authors. Published by Elsevier B.V. on behalf of European Society for Radiotherapy and
Oncology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
1. Introduction
The advent of conformal radiotherapy, as well as the developing
paradigm of image-guided radiotherapy, affords delivery of tumo-
ricidal radiation doses to user-defined target volumes while mini-
mizing dose to proximal organs at risk (OARs). Nonetheless, the
steep dosimetric gradients involved mean that even minor geo-
metric uncertainties may result in substantial dose variation which
may in turn reduce delivered dose to the tumor and/or increase
exposure to radiosensitive tissues [1,2].
In an effort to ameliorate toxicity, improve clinical outcomes
and increase the overall therapeutic ratio, incorporation of multi-
modality imaging inputs in the target volume delineation process
has become normative for specific organ sites. The addition of mul-
timodality imaging parameters, such as fluorodeoxyglucose posi-
tron emission tomography fused with computed tomography
(FDG PET-CT) [3], and magnetic resonance imaging (MRI), has been
demonstrated in several series to improve reproducibility of target
volume definition among users in selected anatomic applications
[4,5]. Additionally, temporal imaging techniques, like 4D-CT or
cine-MR have increasingly been explored as a mechanism to accu-
rately localize the target and OARs, and/or reduction of geometric
margins required to ensure adequate dose prescription (i.e. plan-
ning target volume ‘PTV’ reduction) [6].
Cooperative group studies that plan to implement these novel
forms of image-guided radiotherapy (IGRT) in protocols necessi-
tate consideration of target volume variability as a function of
quality control [7]. Even minor geometric variation in target vol-
umes may impact local control outcomes. Additionally, it is known
that clinical trial radiation deviation may result in measurable
decrement in clinical outcomes [8]. Furthermore, while medical
physics quality assurance parameters face strict scrutiny, multi-
center clinical trials may enroll patients from diverse radiation
treatment centers. Radiation oncologists may vary regarding
degree of expertise in target delineation generally, unknown acu-
men in target delineation within the anatomic region of interest,
and/or unknown standard practices of incorporating either func-
tional imaging (FDG PET, FDG PET-CT) or temporally-indexed
imaging (4D-CT) into target definition9. Even when the aforemen-
tioned clinical practices are known, the practical consistency by a
given center may still vary.
Efforts are increasingly made to formalize target volume strate-
gies (e.g. the recent advent of standardized nodal atlases) [10,11],
and educate radiation oncologists regarding specific expert-
derived skillsets (e.g. ASTRO IMRT guidelines and symposia) [12].
Nonetheless, there remains scant data regarding how to optimize
clinical trial protocol implementation of multimodality functional
imaging combined with temporal information (e.g. 4D-CT) [13].
This represents an unmet need given the fact that 4D-CT is cur-
rently the standard-of-care for RT planning of potentially curative
lung cancers [14]. Furthermore, a recent systematic review by
Frood et al. [15] shed some light on the discrepancies in target vol-
ume definition using 4D FDG PET-CT versus 3D FDG PET-CT.
Moreover, quality assurance studies using computer-estimated
consensus contours have been tested in multiple cancer sites [16–
18], however -to our knowledge- not specifically in Pancoast
tumors. Thus, in addition to testing the feasibility of computer-
generated consensus contouring with multimodality functional
and/or temporal imaging, we sought to assess inter-observer vari-
ability in the setting of Pancoast tumor contouring. Guideline
adherence may theoretically reduce the risk of radiation-induced
toxicities such as brachial plexopathy [19] or pneumonitis [20].
Consequently, the Southwest Oncology Group (SWOG) Radia-
tion Treatment Committee designed this prospective in-silico qual-
ity assurance pilot study to determine how diverse institutions
participating in clinical trials are incorporating FDG PET-CT, 3D-,
and 4D-CT data in RT planning. Additionally, we sought to provide
insight into how such integration might be optimized, standard-
ized, and scrutinized by central review boards, like the IROC Rhode
Island (formerly QARC).
The specific aims of this study are to:
1. Determine the feasibility of multi-site electronic data collection
methods for evaluation of target delineation and user survey.
2. Summarize the effect of 4D-CT incorporation upon target vol-
ume delineation as assessed by custom target delineation eval-
uation software.
3. Determine specific criteria for target volume ‘‘credentialing” in
trials where IMRT is to be implemented.
4. Generate pilot data and testable hypotheses for future research
efforts.
2. Material and methods
This study was approved by the SWOG Radiation Therapy Com-
mittee for execution [21], and started accruing radiation oncolo-
gists in spring 2012. The study was designed in a multi-user
fashion combining objective evaluation of specific target delin-
eation and dose parameters with user reported data. Pancoast
tumors were selected as test cases for this concept study; given
the relatively strong agreement on target and OARs delineation
among radiation oncologists [22,23]. Radiotherapy guidelines were
drafted and multimodality simulation images were acquired as a
part of a then-existing SWOG Pancoast tumor clinical trial protocol.
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2.1. Data
2.1.1. Scans and simulation guidelines
Non-contrast-enhanced CT simulation scans–both bone and
soft tissue windows- were acquired from four patients with Pan-
coast tumors from a single center. These DICOM (Digital Imaging
and Communications in Medicine) files belonged to actual patients
treated with radiotherapy (RT), albeit without any Health Insur-
ance Portability and Accountability Act of 1996 (HIPPA)-defined
patient-specific information [24]. This was performed by
anonymizing patient DICOM datasets using ‘DCMAnonymize’
DICOM Validation Toolkit (https://www.dvtk. org). This software
tool removes all patient specific data (e.g. name, ID codes, date of
scan, gender) from DICOM file headers.
Two patients had simulation 4D-CT and 18-FDG-FDG PET-CT
scans while two patients had simulation 3D-CT and FDG-FDG
PET-CT scans. The 4D-CT scans were contoured using an average
CT that was generated by averaging 4D CT acquisitions over ten
phases of the full breathing cycle. These scans were made available
on the IROC Rhode Island (formerly QARC), website at www.QARC.
org for participants to download scans, instructions and participa-
tion survey. IROC Rhode Island provides radiation therapy, diag-
nostic imaging and data management services for SWOG among
other National Clinical Trials Network (NCTN) institutes [25]
(Fig. 1).
2.1.2. Summary of thoracic radiotherapy
All contouring efforts for this study were undertaken on partic-
ipants’ treatment planning system (TPS) of choice, provided the
capacity for DICOM-RT export was present.
Participants were supplied with relevant imaging and clinical
evaluation information to help them define target volumes pre-
cisely. Additionally, a priori definitions for target volumes, organs
at risk, dose prescription and constraints were specifically pro-
vided as a part of broader consensus guidelines. For example, clin-
ical target volume (CTV) for radiation fields was defined as the
primary tumor, plus involved mediastinal, ipsilateral paratracheal
lymph nodes (levels 2 and 4), and ipsilateral supraclavicular nodes.
The total planned dose was set to be 54 Gy prescribed to an isodose
line that encompassed the planning target volume (PTV) and that
satisfies the dose uniformity guidelines. Participants were tasked
to create an intensity-modulated RT (IMRT) plan for a treatment
course that was to be delivered in 30, once daily fractions of
1.8 Gy each, to a total dose of 54 Gy to the PTV. The percent of nor-
mal lung volume receiving 20 Gy or more (V20) must be kept at
less than 37%. 54 Gy was chosen in anticipation of testing this dose
in a future prospective, cooperative group combined-modality
clinical trial for Pancoast tumors.
2.1.3. Target volume definition
To that end, the definitions of tumor and target volumes as well
as guidelines for delineation were clearly provided for participants.
These were in accordance with International Commission on Radi-
ation Units and Measurements (ICRU) Reports 50 and 62 in order
to mitigate sources of delineation congruency among participants
[26,27]. The instructions included standardized nomenclature of
target volumes, hence facilitating subsequent analysis in a time-
efficient manner. Tumor volumes encompassed gross tumor vol-
ume (GTV) either of the primary tumor (GTV_P) or the clinically
positive lymph nodes (GTV_N). Other target volumes included:
clinical target volume (CTV), planning target volume (PTV), and
internal target volume (ITV). Detailed descriptions are depicted
in Table 1. Of note, the fourth set of scans belonged to a patient
with no nodal disease, hence no GTV_N delineation was required.
2.1.4. Prescribed doses and fractionation guidelines
The total planned dose was set to be 54 Gy prescribed to an iso-
dose line that encompassed the PTV and that satisfied the dose uni-
formity guidelines. The 54 Gy dose was based upon SWOG
recommendations to incorporate higher doses than the classic
45 Gy (per SWOG-9416 and SWOG-0220) for Pancoast trials [28–
30]. This was to be planned as thirty, once daily fractions of
1.8 Gy. The entire PTV was to receive at least 93% of the protocol
dose and a contiguous volume of no>2 cc within the PTV was not
to exceed 120% of the protocol dose [31].
Fig. 1. SWOG in-silico study tasks completed via the IROC Rhode Island platform.
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2.2. Participants
Seventeen SWOG-affiliated radiation oncology participants
(physicians), with median career experience of 11 years (IQR:
2.5–18.75), independently delineated treatment target volumes
as well as OARs. Each participant used his/her preferred TPS for tar-
get delineation. Moreover, six board-certified thoracic radiation
oncologists were designated as the ‘Experts’ for this study. Selec-
tion criteria for ‘Experts’ included all the following: (1) board cer-
tification in radiation oncology; (2) a minimum of 10 years of
practice; Thoracic radiation oncology subspecialty. After plan com-
pletion, each participant, identified by a specific ID and login, sub-
mitted the plan via the internet using FTP transfer (www.qarc.org).
Recorded information extracted from the contouring session were
then available for central analysis.
2.3. Data submission and curation
Target, plan, and dose data were collected centrally via the
QARC platform. Analysis was performed using quantitative
software-assisted analysis of contour, dose and imaging data. Each
participant was asked to fill out an on-line survey assessing subjec-
tive responses to contouring tasks. This survey was made available
via QARC website. It included categorical Likert scale evaluation of
institutional practices regarding FDG PET/CT and 4DCT incorpora-
tion into target delineation, as well as subjective responses regard-
ing the implemented target delineation instruction materials, TPS
used, applied software tool for FDG PET-CT registration and 4D-
CT analysis, among others (Supplementary Material 1).
After data collection was completed, plan suitability analysis
was performed. Designated Experts evaluated each contouring ses-
sion in order to determine if the plan was clinically acceptable
without modification, or whether it represented a major or minor
deviation from expert-determined acceptability, using criteria as
specified in the initial protocol.
2.4. Imaging analytics and evaluation metrics
The six designated Experts’ contours were incorporated into the
final definition of target volumes to serve as comparators for sub-
sequent analysis. This expert composite, i.e. ground truth, was con-
structed using Warfield’s Simultaneous Truth and Performance
Level Estimation (STAPLE) algorithm, a feature embedded in Elekta
ABAS (Atlas-based auto-segmentation software) (http://www.
elekta.com/ABAS). Segmentation simply implies ‘‘classifying”
whether each image voxel belongs to the volume of interest or
the background. The STAPLE algorithm allows for multiple seg-
mentations fusion by automatically estimating the segmentation
Table 1
Definitions and specified designations for target volumes of interest: instructions for participants.
Target volume Definition Specified
designation
Gross tumor volume
(GTV)
The primary tumor (GTV_P) and clinically positive lymph nodes (GTV_N) seen on the pretreatment PET scan (standardized
uptake value; SUV > 3), diagnostic CT scan, and/or treatment planning CT (>1 cm short axis diameter) will comprise the GTV.
The GTV will always be located in the apex of the ipsilateral lung in this particular study. This volume(s) may be disjointed.
GTV_P
GTV_N
Internal target volume
(if used)
The ITV includes the envelope that encompasses the tumor motion for a complete respiratory cycle. ITV
Clinical target volume The CTV is defined to be the GTV plus a 0.5 cm to 1 cm margin as appropriate to account for microscopic tumor extension.
The ipsilateral paratracheal lymph nodes (levels 2 and 4) and supraclavicular fossa lymph nodes will be defined as
comprising part of the CTV for this protocol. If an ITV approach is used then the ITV plus 0.5 cm to 1 cm is added to the ITV to
form the CTV. Elective treatment of the entire mediastinum will not be done. If a uniform margin is used for CTV expansion,
please specify CTV_xxMM, where xx = the margin expansion in millimeters, as structure name (e.g. CTV_05MM denotes a
5 mm expansion margin); if a non-uniform margin is used, please designate the volume CTV.
CTV
Planning target
volume
The PTV margin should account for setup uncertainties and may be individualized. The PTV will comprise the CTV with a
minimum 0.5 cm (if daily imaging correction will be used), or a minimum 1.0 cm if daily imaging will not be performed. If a
uniform margin is used for PTV expansion, please specify PTV_xxMM, where xx = the margin expansion in millimeters, as
structure name (e.g. PTV_05MM denotes a 5 mm expansion margin); if a non-uniform margin is used, please designate the
volume PTV.
PTV_xxMM
Fig. 2. (A) Defining ‘ground truth’ and (B) comparing individual contours against ‘ground truth’ (The green volume in the center of each figure represents the Experts’
composite). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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quality (as characterized by the sensitivity and specificity parame-
ters) of each classifier while simultaneously deriving a weighted
combination of multiple classifiers [32]. This approach provides a
probabilistic estimate of the true delineation and a measure of
the performance level represented by each expert user (Fig. 2A).
Contours by each of 17 participants were then compared with
the experts’ STAPLE composite contour, i.e. ground truth
(Fig. 2B). The following evaluation metrics were used to assess
delineations similarity:
A. Dice Similarity Coefficient [33]: a spatial overlap index and a
reproducibility validation metric. The value of a DSC ranges
from 0, indicating no spatial overlap to 1, indicating com-
plete overlap between two sets of binary segmentation
results [34] (Fig. 3A),
B. Hausdorff metric: gives the mean (Mean Surface Distance) or
the largest length (Maximum Hausdorff Distance) out of the
set of all distances between each point of a set (individual
contour) to the closest point of a second set (expert compos-
ite) [35] (Fig. 3B),
C. Volume Overlap Ratio (VOR, or the Jaccard similarity coeffi-
cient) was computed to represent the ratio of the volume
of intersection to the volume of union per target volume
(TV) per case [36] (Fig. 3C). All three aforementioned metrics
were calculated using a commercially available image regis-
tration software (VelocityAITM 3.0.1)
D. Intraclass correlation coefficient (ICC) was calculated as a
measure of concordance of clustered segmentations
between participants using IBM SPSS Statistics 22.0. The
ICC is basically a signal-to-noise ratio, where higher values
close to 1 indicate higher concordance between volumes of
the same group [37].
2.5. Statistical analysis
Based on estimates from our previous pilot series [7], power
and sample size analysis (G*Power 3 statistical software) [38]
was performed, assuming a minimum possible asymptotic relative
efficiency of 0.86423, using an a priori power goal 1-b of 0.8, non-
Bonferroni corrected one-tailed a = 0.5, for detection of an effect
size of 0.8 (large effect). This resulted in a minimum requisite sam-
ple size of at least 16 participants, hence the inclusion of 17 radi-
ation oncologists.
Statistical assessment was performed using JMP v 11Pro (SAS
institute, Cary, NC). One-way analysis of variance (ANOVA) was
applied to assess whether there were any statistically significant
differences among the mean values of evaluation metrics per tar-
get volume. Additionally, the differential impact of incorporating
3D-CT versus 4D-CT on delineation accuracy was assessed using
the ANOVA test.
3. Results
Seventeen SWOG-affiliated physicians, with median career
experience of 11 years (IQR: 2.5-18.75) participated in this study.
Of note, four out of 17 participants didn’t submit the
questionnaires.
In this paper, we’re reporting target volume variation, namely:
GTV_P, GTV_N, CTV, and PTV in comparison to reference expert
composites. We excluded ‘ITV’ from our analysis as the vast major-
ity of participants didn’t assign them. More importantly, there
were not enough expert ‘ITV’ contours per case to feed into the
STAPLE algorithm to define the ‘ground truth’. Almost all other tar-
get volumes in all 4 cases were not unanimously retrievable from
QARC database or contoured by 17 participants (range: 9–17 con-
tours/target volume/case).
Moreover, GTV_N contours showed some inter-observer vari-
ability of included thoracic nodal stations. One example was
GTV_N in case #1. Out of 12 available delineations of GTV_N: 2
participants delineated (1L) nodal station, 5 participants included
stations (3A) and (6), while the rest included all 3 stations. All con-
tours were included in the analysis as long as there were sufficient
expert contours to serve as an input to the STAPLE algorithm to
define the ground truth.
For each case, all 4 evaluation metrics mentioned in the ‘Meth-
ods’ section were derived by comparing individual participants’
target volumes to the corresponding Experts’ STAPLE composite.
Median values and corresponding interquartile ranges are also pro-
vided in Table 2. When compared to Experts’ STAPLE, GTV_P had
the best agreement among all participants with median DSC of
Fig. 3. Evaluation metrics for assessment of delineations similarity; (A) Dice similarity coefficient, (B) Hausdorff distance (HD), and (C) Volume overlap ratio. (FN: false
negative; TP: true positive; FP: false positive; TN: true negative).
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0.87. On the contrary, GTV_N demonstrated the lowest agreement
with median DSC of 0.35 as shown in Fig. 4. Likewise, GTV_P
demonstrated the lowest median HD & MSD values; 12.6 mm
and 0.37 mm, respectively. Whereas, GTV_N showed the largest
median HD and MSD values; 68.27 and 17.5, respectively (Figs. 5
and 6).
In between lies PTV and CTV which were associated with the
second and third best median DSC, respectively (Fig. 4). Similarly,
the second and third highest HD and MSD were reported with
CTV and PTV as tabulated in Table 2 and shown in Figs. 5 and 6.
The median VOR for all TVs in the included 4 cases was 0.14 (range
0–0.67). Along the same lines, the VOR was consistently highest for
GTV_P and lowest for GTV_N across all 4 cases. Given the inter-
observer variability in selection of included lymph node stations,
the GTV_N VOR was calculated based on the volumes segmented
by group of participants with most harmonious approach (6 out
of 12). Intraclass correlation coefficients (ICC) for DSC, HD, MSD
metrics are also reported in Table 2.
Interestingly, there were no statistically significant differences
in all studied metrics for all TVs for cases with 4D-CT (i.e. con-
toured on average CT) versus cases with 3D-CT simulation scans
(Fig. 7). Table 2 depicts the number of participants’ delineations
for each of the studied TVs as well as medians and interquartile
ranges (IQRs) of all individual metrics derived from all cases.
4. Discussion
Target delineation is a key element in modern radiotherapy
treatment planning, particularly following the introduction of
intensity modulated radiotherapy (IMRT)[39]. Accurate target
identification has become as important as beam delivery to ensure
tumor coverage, and reduce unnecessary normal tissue exposure
[40]. Despite efforts to provide guidelines for more reproducible
target delineation across different institutes [14,16,41], inter-
observer variations are still a barrier that faces multi-
Table 2
Median values of individual metrics of all-participants’ delineations across all cases; including interquartile ranges (DSC = Dice coefficient; HD = maximum Hausdorff distance;
MSD = Mean Surface Distance; GTV_P = gross primary tumor volume; GTV_N = gross nodal tumor volume; CTV = clinical target volume; PTV = planning target volume;
mm = millimeters; IQR = Inter-Quartile Range).
GTV_P GTV_N CTV PTV
Number of participants
Case 1 13 12 16 17
Case 2 14 9 16 16
Case 3 15 13 15 15
Case 4 16 0 16 16
DSC median (IQR) 0.87 (0.78–0.94) 0.35 (0.10–0.46) 0.80 (0.72–0.90) 0.81 (0.70–0.90)
HD median in mm (IQR) 12.6 (10.09–17.75) 68.27 (41.20–80.31) 43.73 (23.48–64.90) 34.22 (24.80–59.18)
MSD median in mm (IQR) 0.37 (0.15–0.81) 17.5 (8.5–25.45) 2.03 (0.40–4.31) 1.56 (0.64–3.98)
VOR (%)
Case 1 21.9 7.1* 14 13
Case 2 67.1 0 46.4 48.1
Case 3 41 0 23.8 28
Case 4 7.2 N/A** 4.4 9.9
* Given the inter-observer variability in selection of included lymph node stations, this VOR was calculated based on the volumes segmented by group of participants with
most harmonious approach (6 out of 12).
** N/A: Not Applicable because this scan belongs to a patient with no nodal disease.
Fig. 4. One-way analysis of Variance of Dice similarity coefficient across target volumes. (Green diamonds represent mean and standard deviation; and red boxes encompass
interquartile ranges with the transverse line representing median value). (For interpretation of the references to colour in this figure legend, the reader is referred to the web
version of this article.)
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institutional trials [2]. Another barrier is the absence of an opti-
mized protocol to account for different imaging modalities when
it comes to RT planning for Pancoast tumors [22]. Consequently,
our group sought to quantitatively determine the inter-observer
variability of expert radiotherapy target-volume delineation for
Pancoast tumors, towards developing an expert-consensus con-
touring atlas.
Per our study, we have shown that the best agreement was in
GTV_P across all participants when compared to experts’ STAPLE
with a median Dice coefficient of 0.873 (range 0.781–0.935). Also,
we showed that the lowest agreement was in GTV_N with a med-
ian DSC of 0.347 (range 0.095–0.458). No statistically significant
difference was shown between different imaging simulation scans
(i.e. 4D-CT and 3D-CT).
Some limitations faced our study including long time taken by
experts and other participants to complete the needed contours
(an average of 18 months). The 4D-CT scans were contoured using
only a single static time point (i.e. different phases of respiration
were not accounted for), which may explain why a statistically sig-
nificant difference was not detected between 3D-CT and 4D-CT
simulation studies. Of note, participants used FDG PET images to
define tumor volumes for all four cases. Consequently, investigat-
Fig. 5. One-way analysis of Variance of maximum Hausdorff distance across target volumes. (Green diamonds represent mean and standard deviation; and red boxes
encompass interquartile ranges with the transverse line representing median value). (For interpretation of the references to colour in this figure legend, the reader is referred
to the web version of this article.)
Fig. 6. One-way analysis of Variance of mean surface distance (MSD) across target volumes. (Green diamonds represent mean and standard deviation; and red boxes
encompass interquartile ranges with the transverse line representing median value). (For interpretation of the references to colour in this figure legend, the reader is referred
to the web version of this article.)
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ing the value of FDG PET fusion in improving or standardizing tar-
get volumes delineation was not feasible. The selection of partici-
pants was limited to SWOG institutions which might represent a
selection bias. Some target volumes contours were not included
in the analysis of all 4 cases. This was attributed to either available
contours being not retrievable from IROC Rhode Island database or
contours not originally made by all 17 participants (range: 9–17
contours available for analysis per target volume for each case).
The instruction set assigned GTV_N to the clinically positive
lymph nodes seen on pre-treatment PET scan (SUV > 3), diagnostic
CT scan, and/or treatment planning CT (>1 cm short axis diameter).
However, wide inter-observer variability in GTV_N contours was
observed. This is chiefly attributed to neither enumerating affected
thoracic nodal stations in the instruction set nor suggesting stan-
dardized reference lymph node mapping atlas; another two areas
for improvement for future studies [11,42]. A similar study by Mer-
cieca et al also named interpretational differences among obser-
vers as the leading cause for large variations in GTV_N
delineation [43]. For example, in case #2, among the 9 participants
who delineated GTV_N, only 3 participants included the same
nodal stations. On the other hand, the remaining 6 participants
included partly or completely different nodal stations in 5 different
permutations. This significantly affected the interpretability of the
overlapping/similarity metrics we selected for evaluating inter-
observer delineation agreement. Similarly, GTV_N VOR was calcu-
lated as zero for cases #2 and #3.
To avoid this pitfall in case #1, GTV_N VOR was calculated
based on volumes segmented by group of participants with most
harmonious choice of nodal stations (6 out of 12). Also, it was dif-
ficult to interpret DSC for GTV_N given the small size of lymph
nodes and the multiple non-contiguous objects within one VOI,
i.e. one GTV_N volume may encompass multiple affected lymph
nodes. Hausdorff distance may represent an appropriate alterna-
tive in such a situation where the probability of overlap is small
[44].
Nonetheless, this study represents one of the earliest multi-
institutional efforts to automate target volume delineation quality
assurance for Pancoast tumors. To that end, fully anonymized
inter-institutional data sharing was optimized via the IROC Rhode
Island platform. Additionally, we provided all the participating
radiation oncologists with contouring guidelines, target volumes
definitions and standardized nomenclatures.
Our work follows previous SWOG efforts made to address inter-
observer variability across different organs sites [9]. In previous
work, we showed that educational intervention with a SWOG-
approved consensus atlas reduced inter-observer variability in rec-
tal cancer target volume delineation [7]. However, that study was
performed using a CT-only dataset. The goal of the present study
was quantitative assessment of variation in target volumes delin-
eation for Pancoast tumors in a clinical trial group setting.
Previous work by other groups suggested that atlas and real
time feedback hugely improve OARs delineation in head and neck
cancers [45]. Similar results were reported by the Australasian Gas-
trointestinal Trials Group (AGITG), showing that planning guideli-
nes could be significantly improved and help radiation oncologists
optimize IMRT delivery in anal cancer [41]. Another study was also
conducted to assess atlas implementation effect on anorectal tar-
get delineation, and also showed that use of atlas and contouring
guidelines do reduce inter-observer variability [46].
The authors of this study are planning to expand these pilot
data into a protocol designed to serve as a template for future
SWOG studies involving radiotherapy for Pancoast tumors. By pro-
viding clear instructions, well-defined standardized criteria and
subsequent calibration tool for target delineation, future multi-
institutional studies could execute credentialing/QA efforts. That
would invariably facilitate the task of central review boards for
multi-institutional clinical trials in a timely- and cost-effective
manner. These results can also be integrated into development of
educational tools for residency training programs or continued
medical education programs to help clinicians improve their target
delineation skillset [47].
5. Conclusions
In conclusion, a relatively high degree of inter-observer varia-
tion was noted for all target volumes except for GTV_P, revealing
Fig. 7. One-way analysis of Variance of maximum Hausdorff distance by simulation imaging modality. (Green diamonds represent mean and standard deviation). (For
interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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potentials for future protocol modifications to improve the accu-
racy, and reduce the variability of target volume definitions. This
study helps explain the variance that can be seen between radia-
tion oncologists treating the same patient and thus provides a tool
to better understand and assess the acceptable range of treatment
volumes satisfactory to meet QA standards.
6. Link to research Data
https://www.qarc.org/
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